Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer.
- Author:
Young Il KIM
1
;
Soo Jeong CHO
;
Jong Yeul LEE
;
Chan Gyoo KIM
;
Myeong Cherl KOOK
;
Keun Won RYU
;
Young Woo KIM
;
Il Ju CHOI
Author Information
- Publication Type:Original Article
- Keywords: Helicobacter pylori; Stomach Neoplasms; Gastrectomy; Survival
- MeSH: Follow-Up Studies; Gastrectomy*; Gastric Mucosa; Gastric Stump; Helicobacter pylori*; Helicobacter*; Humans; Kaplan-Meier Estimate; Male; Mortality; Multivariate Analysis; Prospective Studies; Recurrence; Risk Factors; Stomach Neoplasms*
- From:Cancer Research and Treatment 2016;48(3):1020-1029
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Negative Helicobacter pylori status has been identified as a poor prognostic factor for survival in gastric cancer (GC) patients who underwent surgery. The aim of this study was to examine the effect of H. pylori eradication on long-term outcomes after distal gastrectomy for GC. MATERIALS AND METHODS: We analyzed the survival of 169 distal GC patients enrolled in a prospective randomized trial evaluating histologic changes of gastric mucosa after H. pylori eradication in the remnant stomach. The outcomes measured were overall survival (OS) and GC recurrence rates. RESULTS: The median follow-up duration was 9.4 years. In the modified intention-to-treat analysis including patients who underwent H. pylori treatment (n=87) or placebo (n=82), 5-year OS rates were 98.9% in the treatment group and 91.5% in the placebo group, and Kaplan-Meier analysis showed no significant difference in OS (p=0.957) between groups. In multivariate analysis, no difference in overall mortality was observed between groups (adjusted hazard ratio [aHR] for H. pylori treatment, 0.75; p=0.495) or H. pylori-eradicated status (aHR for positive H. pylori status, 1.16; p=0.715), while old age, male sex, and advanced stage ≥ IIIa were independent risk factors. Six patients in the treatment group (6.9%) and seven patients in the placebo group (8.5%) had GC recurrences, and GC recurrence rates were not different according to H. pylori treatment (5-year GC recurrence rates, 4.6% in the treatment group vs. 8.5% in the placebo group; p=0.652). CONCLUSION: H. pylori eradication for GC patients who underwent distal gastrectomy did not compromise long-term survival after surgery.
